Non-metastatic metaplastic triple-negative breast cancer with residual disease after chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Metaplastic triple-negative breast cancer; HER2 0

The patient had an initial partial response to neoadjuvant chemotherapy but then progressed before surgery. Modified radical mastectomy found substantial residual metaplastic carcinoma with 0/21 nodes involved, followed by adjuvant radiotherapy and metronomic capecitabine.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Stage III HER2-Positive Breast Cancer: Caroline's Patient Story

Patient Info: Caroline McNally, Female, Under 40 | Stage III

Biomarkers: Hormone-positive component reported; exact ER/PR/HER2 panel not stated

As of February 2026, Caroline was in active treatment for Stage III hormone-positive breast cancer, receiving Taxol after dose-dense AC and preparing for double mastectomy, likely radiation, and hormone therapy.

Stage IIIB triple-negative metaplastic breast cancer: urgent mastectomy and reconstruction after rapid progression on neoadjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; nuclear grade 3

At 18-month follow-up, she was disease-free after urgent mastectomy, axillary dissection, flap/skin-graft reconstruction, resumed chemotherapy, and radiation for rapidly progressive triple-negative metaplastic breast cancer.

PubMed CentralRead more →

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed CentralRead more →

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed CentralRead more →

Localized male small-cell neuroendocrine breast cancer with complete response

Patient Info: Anonymized, Male, 40s

Biomarkers: Synaptophysin-positive; weak cytokeratin-positive; HER2-negative; Ki-67 greater than 70%; genetic testing not performed

The tumor shrank substantially during neoadjuvant cisplatin/etoposide. Modified radical mastectomy then showed a complete pathologic response and 17 reactive axillary lymph nodes; the patient remained disease-free after 18 months of follow-up.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Stage II Invasive Lobular Carcinoma: Tamra's Patient Story

Patient Info: Tamra, Female | Stage II

Biomarkers: MammaPrint genomic analysis pending/under consideration

As of January 2026, Tamra had chosen partial mastectomy with radiation and concurrent bilateral reconstruction for Stage II invasive lobular breast cancer, with chemotherapy decision dependent on MammaPrint results.

Lobular Breast Cancer AllianceRead more →

Stage IV HER2-Positive Breast Cancer: Sonja's Patient Story

Patient Info: Sonja Rideout, Female | Stage IV

Biomarkers: HER2-positive; Tempus testing later indicated immunotherapy as an option

Metastatic Site: Lungs; liver; bone: tailbone; thoracic lymph nodes

As of January 2026, Sonja was living with metastatic HER2-positive breast cancer after spread to lungs and liver, later tailbone and thoracic lymph nodes, and had moved to weekly carboplatin/gemcitabine plus monthly immunotherapy.

Breast cancer history with silicone lymphadenitis mimicking recurrence

Patient Info: Anonymized, Female, 70+

Workup of suspicious internal mammary and axillary lymph nodes found silicone-induced lymphadenitis from implant rupture, not breast cancer recurrence or metastasis.

PubMed CentralRead more →

Stage III Breast Cancer Treatment Complicated by Coronary Thrombosis

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 25–30%

She achieved complete remission about 12 months after the myocardial infarction and remained in complete oncologic remission at 44 months.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Sian's Survivor Story

Patient Info: Sian Bevans, Female, 50s | Stage II

Biomarkers: Triple-positive

Sian was 11 years past diagnosis, completed 10 years of maintenance medication in May 2025, and reported feeling more like herself; no recurrence was described.

Cleveland ClinicRead more →

Stage IV Breast Cancer: Lea's Patient Story

Patient Info: Lea, Female, Under 40 | Stage IV

Metastatic Site: Bone: hip sockets, femurs, spine; liver

As of January 2026, Lea was living with metastatic breast cancer involving bone and liver and was in active treatment with Taxol after progression changed her treatment plan.

Left breast carcinoma with neuroendocrine differentiation: partial mastectomy and node-negative surgery

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive breast cancer with ER/PR-negative status and neuroendocrine markers.

Surgery was completed without perioperative complications and no recurrence or metastasis was noted before the patient was lost to follow-up; long-term status is unavailable.

PubMed CentralRead more →

Triple-negative breast cancer with occult metastasis in parathyroid and ectopic thyroid adenomas: complete remission after chemotherapy

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Triple-negative breast cancer. Metastatic deposits were CK7 positive and negative for ER, HER2

Metastatic Site: parathyroid adenoma; ectopic thyroid adenoma /…

As of December 2025, she remained in complete remission 1 year after systemic chemotherapy for triple-negative breast cancer with occult metastatic deposits in parathyroid and ectopic thyroid adenomas.

PubMed CentralRead more →

Young Woman With Breast Cancer and Four Inherited Cancer-Risk Variants

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ER 40%; PgR 60%; HER2 0; Ki-67 25%; germline pathogenic variants in ATM, PALB2, PMS2

Metastatic Site: brain

The breast cancer spread rapidly to the brain, and she died within a few months.

PubMed CentralRead more →

Glycogen-rich clear cell breast carcinoma: HER2-positive early-stage case with disease-free follow-up

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; HER2-positive; PR-negative; Ki-67 ~10%; intracytoplasmic glycogen confirmed

At 1-year follow-up, she had no evidence of breast cancer recurrence.

PubMed CentralRead more →

Luminal B-like lobular breast cancer: robotic-assisted nipple-sparing mastectomy with 12-month disease-free follow-up

Patient Info: Anonymized, Female, 40s

Biomarkers: ER 90%; PR 100%; HER2-negative; Ki-67 20%; luminal B-like subtype

As of November 2025, she was disease-free 12 months after neoadjuvant taxane-based chemotherapy and single-port robotic-assisted nipple-sparing mastectomy with immediate reconstruction.

PubMed CentralRead more →

I Was Told I Was TOO YOUNG For Breast Cancer!

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: mediastinum; lymph nodes between the lungs

As of November 2025, the patient was living with Stage IV metastatic breast cancer, described as lifelong and requiring ongoing treatment. She had also completed local treatment for a later breast lesion.

YouTube — The Patient StoryRead more →

Synchronous EGFR-mutated lung adenocarcinoma and metastatic breast cancer: surgery and adjuvant therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Two cancers: lung adenocarcinoma with EGFR exon 19 deletion; breast cancer ER-positive, PR-low, HER2 non-amplified.

Metastatic Site: lung

Follow-up CT on 26 December 2024 showed no recurrence, with disease-free survival estimated at 27 months to 1 April 2025 while on icotinib and letrozole maintenance.

PubMed CentralRead more →

Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

HER2-positive DCIS with KLHL11 encephalitis and pulmonary adenocarcinoma in situ

Patient Info: Anonymized, Female, Under 40 | Stage 0

Biomarkers: Breast DCIS was ER/PR positive and HER2 positive

After local breast treatment and later lung resection, she was asymptomatic on levetiracetam and tamoxifen, with no recurrent fever, seizures, or ataxia reported.

PubMed CentralRead more →